RESUMO
OBJECTIVES: Arterial calcification due to deficiency of CD73 (ACDC) is a hereditary autosomal recessive ectopic mineralization syndrome caused by loss-of-function mutations in the ecto-5'-nucleotidase gene. Periarticular calcification has been reported but the clinical characterization of arthritis as well as the microstructure and chemical composition of periarticular calcifications and SF crystals has not been systematically investigated. METHODS: Eight ACDC patients underwent extensive rheumatological and radiological evaluation over a period of 11 years. Periarticular and synovial biopsies were obtained from four patients. Characterization of crystal composition was evaluated by compensated polarized light microscopy, Alizarin Red staining for synovial fluid along with X-ray diffraction and X-ray micro tomosynthesis scanner for periarticular calcification. RESULTS: Arthritis in ACDC patients has a clinical presentation of mixed erosive-degenerative joint changes with a median onset of articular symptoms at 17 years of age and progresses over time to the development of fixed deformities and functional limitations of small peripheral joints with, eventually, larger joint and distinct axial involvement later in life. We have identified calcium pyrophosphate and calcium hydroxyapatite (CHA) crystals in SF specimens and determined that CHA crystals are the principal component of periarticular calcifications. CONCLUSION: This is the largest study in ACDC patients to describe erosive peripheral arthropathy and axial enthesopathic calcifications over a period of 11 years and the first to identify the composition of periarticular calcifications and SF crystals. ACDC should be considered among the genetic causes of early-onset OA, as musculoskeletal disease signs may often precede vascular symptoms.
Assuntos
5'-Nucleotidase/deficiência , Calcinose/diagnóstico por imagem , Artropatias/diagnóstico por imagem , Periartrite/diagnóstico por imagem , Doenças Vasculares/diagnóstico por imagem , 5'-Nucleotidase/genética , Calcinose/genética , Calcinose/patologia , Pré-Escolar , Feminino , Proteínas Ligadas por GPI/genética , Humanos , Artropatias/genética , Artropatias/patologia , Masculino , Pessoa de Meia-Idade , Periartrite/genética , Periartrite/patologia , Radiografia , Doenças Vasculares/genética , Doenças Vasculares/patologiaRESUMO
Autoimmune neutropenia (AIN) is defined as a neutrophil count <1.5 × 109/L caused by increased peripheral destruction of neutrophils from an underlying autoimmune mechanism in which autoantibodies are directed against a patient's own neutrophils. AIN has a multifactorial etiology ranging from an idiopathic primary phenomenon to secondary disorders associated with established autoimmune diseases. Primary AIN is more prevalent in children, generally self-limited, and typically manifests as a sole hematologic abnormality. Secondary AIN is more common in adults and often occurs in the setting of concurrent autoimmune diseases, infections, malignancies, or medications. It may be seen posttransplantation or occasionally with neurological diseases. Various laboratory modalities are used to detect anti-neutrophil antibodies. Although biologic agents such as rituximab and alemtuzumab (Campath-1H) have been used in the management of AIN, granulocyte colony-stimulating factor remains the first-line therapy. In this article we provide a review of the pathogenesis of AIN, its clinical presentation, and the current treatment options.
Assuntos
Doenças Autoimunes/etiologia , Neutropenia/imunologia , Adulto , Autoanticorpos/imunologia , Doenças Autoimunes/patologia , Doenças Autoimunes/terapia , Criança , Humanos , Neutropenia/etiologia , Neutropenia/patologia , Neutropenia/terapiaRESUMO
Autoimmune neutropenia, caused by neutrophil-specific autoantibodies is a common phenomenon in autoimmune disorders such as Felty's syndrome and systemic lupus erythematosus. Felty's syndrome is associated with neutropenia and splenomegaly in seropositive rheumatoid arthritis which can be severe and with recurrent bacterial infections. Neutropenia is also common in systemic lupus erythematosus and it is included in the current systemic lupus classification criteria. The pathobiology of the autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus is complex, and it could be a major cause of morbidity and mortality due to increased risk of sepsis. Treatment should be individualized on the basis of patient's clinical situation, and prevention or treatment of the infection. Recombinant human granulocyte colony-stimulating factor is a safe and effective therapeutic modality in management of autoimmune neutropenia associated with Felty's syndrome and systemic lupus erythematosus, which stimulates neutrophil production. There is a slight increased risk of exacerbation of the underlying autoimmune disorder, and recombinant human granulocyte colony-stimulating factor dose and frequency should be adjusted at the lowest effective dose.
Assuntos
Doenças Autoimunes/complicações , Doenças Autoimunes/terapia , Síndrome de Felty/complicações , Síndrome de Felty/terapia , Lúpus Eritematoso Sistêmico/complicações , Neutropenia/etiologia , Neutropenia/terapia , Doenças Autoimunes/tratamento farmacológico , Síndrome de Felty/fisiopatologia , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Humanos , Lúpus Eritematoso Sistêmico/fisiopatologia , Lúpus Eritematoso Sistêmico/terapia , Neutropenia/fisiopatologia , Proteínas RecombinantesAssuntos
Aorta/diagnóstico por imagem , Doenças Assintomáticas , Arterite de Células Gigantes/diagnóstico por imagem , Linfoma Difuso de Grandes Células B/diagnóstico , Síndrome do Roubo Subclávio/diagnóstico por imagem , Artérias Temporais/patologia , Assistência ao Convalescente , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Etoposídeo/uso terapêutico , Fluordesoxiglucose F18 , Fraturas Espontâneas/etiologia , Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/patologia , Humanos , Fraturas do Úmero/etiologia , Achados Incidentais , Linfoma Difuso de Grandes Células B/complicações , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Angiografia por Ressonância Magnética , Masculino , Tomografia por Emissão de Pósitrons , Prednisona/uso terapêutico , Compostos Radiofarmacêuticos , Rituximab/administração & dosagem , Síndrome do Roubo Subclávio/etiologia , Vincristina/uso terapêuticoRESUMO
Breast carcinoma ranks among the most prevalent malignancies in women. Breast carcinoma frequently metastasizes to bone and approximately 70% of patients with breast cancer have bone metastases, which generally are osteolytic lesions. They cause major morbidity and mortality in patients; and the available treatment options are limited. Bone-specific homing and colonization of cancer cells are important and interesting features of metastasis. There are complex and multiple steps in the process of bone metastasis; and the elaborate interaction between breast carcinoma and bone involves various cytokines, growth factors and cellular signals, which results in a vicious cycle and promotes tumor cell accumulation and osteolysis. Recent advances in molecular biology have resulted in major breakthroughs in our understanding of the pathogenesis of bone metastasis in breast cancer, which is critical in preventing metastasis, designing novel and targeted treatments and prolonging survival in this devastating condition.